Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Hematol. 2011 Aug;4(4):427-36. doi: 10.1586/ehm.11.42.

Managing acute promyelocytic leukemia without conventional chemotherapy: is it possible?

Author information

  • 1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. parkj6@mskcc.org

Abstract

The introduction of all-trans retinoic acid in 1985 combined with anthracycline-based chemotherapy has revolutionized the prognosis of acute promyelocytic leukemia (APL) with current complete response rates of more than 90% and cure rates of approximately 80%. The subsequent advent of arsenic trioxide in 1994 marked an additional milestone in APL treatment and has inspired the design of rationally targeted, chemotherapy-free front-line treatment regimens without compromising the excellent outcome achieved by anthracycline-containing protocols. APL is, therefore, a unique subtype of acute myeloid leukemia potentially curable with targeted therapies without any exposure to conventional DNA-damaging chemotherapy. Cure rates of APL can be further increased by implementing management strategies to reduce early hemorrhagic deaths, which remain the major cause of treatment failure with the current therapy.

PMID:
21801134
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk